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Introduction
Despite preventive measures, every year seasonal influ-
enza epidemics cause illness and death worldwide, even 
in developed countries. The appearance of the new A/
H1N1v (A/California/07/09) virus on the world scene 
prompted the WHO and other international and national 
healthcare institutions to draw up and implement strate-
gies aimed at monitoring and containing the spread of 
this pandemic virus [1]. The Italian system of influenza 
surveillance (INFLUNET) was promptly potentiated.
Materials and methods
In Italy, about 1200 general practitioners and independent 
pediatricians send in weekly reports of cases of influen-
za-like illness (ILI) among their patients (over 2% of the 
population of Italy) to two National Reference Centers: 
the CIRI-IV and the National Institute of Health (CNE-
SPS). These centers coordinate the activities of sentinel 
physicians and, after analyzing and processing the data 
sent in, draw up a weekly report of the epidemiologi-
cal trend of the disease, which is promptly published in 
the Italian Clinical Epidemiological Surveillance Web 
sites [2, 3].
In order to estimate the burden of the influenza pandemic, 
we examined the epidemiological data collected over the 
10 previous seasons.
The data reported refer to the activity of surveillance 
carried out in 9 Italian Regions (which account for 
about half of the population of Italy) coordinated by 
the CIRI-IV.
Results
The first case of influenza caused by H1N1v was identi-
fied at the beginning of May, 2009. Sporadic cases were 
identified up to the 38th week o f  2009 (the end of sum-
mer), when the surveillance system revealed an increase 
in the incidence of cases of disease among subjects of 
pediatric age (0-14 years).
The pandemic wave began in the 42nd-43rd weeks of 2009 
and reached its peak in the 45th week. (Fig. 1). Consider-
ing an epidemic threshold value of 2‰, we can conclude 
that the phenomenon lasted 7-8 weeks and that in the 
45th week the pandemic reached its peak (9.97‰).
Stratification of the data on the incidence of infections 
shows that the most severely affected subjects were 
those of pediatric age, especially those of school age. 
Moreover, in this age-group, the pandemic period was 
much longer (14 weeks) and the peaks of incidence were 
much higher than among adult subjects (15-64 years): 
16.4‰, 34.0‰ and 7.0‰, in the age-groups 0-4, 5-14 
and 15-64 years, respectively. Few cases were reported 
among the elderly.
We estimated the numbers of cases of influenza ob-
served during the pandemic period to be 1,108,477 in 
the pediatric age-group, 1,374,709 in the 15-64-year 
age-group and 87,650 among the elderly. If this estimate 
is extended to the entire 2009-2010 influenza season (28 
weeks of surveillance), the figures become 1,823,991, 
2,523,363 and 217,582 in the age-groups 0-14, 15-64 
and over-64 years, respectively (Tab. I).
Comparison of the data on the 2009-2010 pandemic with 
those from the previous influenza seasons reveals that 
the peak incidence was lower than in the 2004-2005 and 
1999-2000 seasons. Indeed, the frequency of cases is 
comparable to that of classic seasonal influenza of mod-
erate intensity. Nevertheless, the pandemic unfolded in 
a very short time.
We have estimated the costs of the influenza seasons from 
1999 to 2010. These costs have been calculated on the 
basis of the epidemiological data, the unit cost per age-
group (€ 212, € 731 and € 1,041 for the age groups 0-14, 
15-64 and ≥ 65 years, respectively) and the purchasing 
power of the Euro (PPC) [4-6]. In Italy, the total costs at-
tributable to influenza in the seasons 1999-2008 amount 
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Fig. 1. CIRI-IV. weekly morbidity for ili and ari (acute respiratory 
infections) (per 1,000 inhabitants) during the 2009-10 influenza 
season.
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to approximately € 15 billion (mean cost per season: 
€ 1,355,565,004). These costs have been calculated on 
the basis of the total numbers of cases observed during 
the seasonal epidemics; they therefore underestimate the 
true economic burden. Indeed, if the total number of cases 
occurring during the entire influenza seasons were to be 
considered, the total cost over the 10 seasons would rise 
from € 15 billion to € 20 billion.
In the 2009-2010 influenza season, the economic burden 
was about € 1,361,000,000 during the pandemic period 
and about € 2,300,000,000 for the entire season.
To these costs, we also have to add the costs of the vac-
cination campaign (purchase of 24 million doses of vac-
cine = € 184,800,00).
Less than 1 million (925,000) doses of vaccine were ad-
ministered during the vaccination campaign. The benefit 
derived from the administration of these 925,000 doses 
was equivalent to about € 18 million (cases of influ-
enza avoided = 35,413); this means a negative balance 
of € 166,789,088. (Fig. 2).
In an ideal situation, in which all 24 million doses would 
have been used (8,428,708 for pediatric subjects and 
15,571,292 for adults), about 1,180,882 cases of influ-
enza could have been avoided (a cost saving of about 
€ 462,680,367), which means a positive balance of 
about € 278 million.













1999-00 dec-feb 10 785,545 2,840,322 400,295 4,026,162 4,890,280
2000-01 Jan-feb 7 769,398 906,098 69,195 1,744,961 2,484,888
2001-02 Jan-mar 10 1,085,297 1,485,351 161,766 2,732,415 3,431,394
2002-03 Jan-mar 10 1,205,461 1,971,888 293,855 3,471,204 4,362441
2003-04 Jan-mar 11 634,396 1,179,531 157,851 1,971,778 2,747,624
2004-05 dec-mar 12 1,250,203 2,693,302 441,689 4,385,195 5,009,445
2005-06 Jan-mar 4 187,435 261,696 27,766 476,897 1,858,832
2006-07 Jan-mar 8 634,138 1,102,093 139,810 1,876,041 2,709,480
2007-08 Jan-mar 11 842,994 1,550,515 194,510 2,588,019 3,302,091
2008-09 Jan-mar 9 629,061 1,282,537 179,961 2,091,559 2,890,422
2009 - - 27,881 91,997 10,876 130,754 576,144
2009-10 oct-dec 7 1,108,477 1,374,709 87,650 2,570,836 4,041,383
Fig. 2. real saving (on the basis of vaccine doses used), ideal sav-
ing (if all vaccine doses had been used) and balance of the vac-
cination campaign conducted in italy against h1n1v virus.
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Conclusions
The 2009-2010 influenza pandemic proved to be com-
parable to other influenza seasons of moderate intensity. 
Nevertheless, evident difficulties and shortcomings can 
be seen in the management of the pandemic. The infor-
mation campaign was insufficient to clarify the potential 
severity of the pandemic; doctors did little to promote 
vaccination, and distribution of the vaccine was delayed. 
These were the main factors responsible for the inad-
equate management which led to a negative balance of 
the vaccination campaign.
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